Impact of overlapping risks of type 2 diabetes and obesity on coronavirus disease severity in the United States.
Aged
Aging
/ pathology
COVID-19
/ pathology
Critical Care
/ statistics & numerical data
Diabetes Complications
/ pathology
Diabetes Mellitus, Type 2
/ pathology
Female
Hospitalization
/ statistics & numerical data
Humans
Hypoglycemic Agents
/ therapeutic use
Intensive Care Units
/ statistics & numerical data
Male
Metformin
/ therapeutic use
Middle Aged
Obesity
/ pathology
Risk Factors
SARS-CoV-2
Severity of Illness Index
Sodium-Glucose Transporter 2 Inhibitors
/ therapeutic use
United States
COVID-19 Drug Treatment
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
09 09 2021
09 09 2021
Historique:
received:
09
02
2021
accepted:
12
08
2021
entrez:
10
9
2021
pubmed:
11
9
2021
medline:
24
9
2021
Statut:
epublish
Résumé
The impact of overlapping risk factors on coronavirus disease (COVID-19) severity is unclear. To evaluate the impact of type 2 diabetes (T2D) and obesity on COVID-19 severity, we conducted a cohort study with 28,095 anonymized COVID-19 patients using data from the COVID-19 Research Database from January 1, 2020 to November 30, 2020. The mean age was 50.8 ± 17.5 years, and 11,802 (42%) patients were male. Data on age, race, sex, T2D complications, antidiabetic medication prescription, and body mass index ≥ 30 kg/m
Identifiants
pubmed: 34504112
doi: 10.1038/s41598-021-96720-x
pii: 10.1038/s41598-021-96720-x
pmc: PMC8429758
doi:
Substances chimiques
Hypoglycemic Agents
0
Sodium-Glucose Transporter 2 Inhibitors
0
Metformin
9100L32L2N
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
17968Informations de copyright
© 2021. The Author(s).
Références
Diabetes Ther. 2020 Dec;11(12):3003-3005
pubmed: 33052538
BMC Med. 2020 Nov 16;18(1):359
pubmed: 33190637
BMJ Open. 2020 Oct 16;10(10):e040638
pubmed: 33067300
Diabetes Obes Metab. 2021 Apr;23(4):886-896
pubmed: 33319454
Sci Rep. 2016 Dec 13;6:38937
pubmed: 27958337
Proc Natl Acad Sci U S A. 2020 Sep 1;117(35):21011-21013
pubmed: 32788355
PLoS One. 2013 Apr 22;8(4):e61763
pubmed: 23630613
N Engl J Med. 2013 Apr 25;368(17):1613-24
pubmed: 23614587
Diabetes Ther. 2020 Jul;11(7):1605-1606
pubmed: 32447736
Adv Ther. 2020 Dec;37(12):4981-4995
pubmed: 33044691
MMWR Morb Mortal Wkly Rep. 2020 Oct 23;69(42):1517-1521
pubmed: 33090984
Obes Rev. 2020 Nov;21(11):e13128
pubmed: 32845580
J Public Health (Oxf). 2020 Aug 18;42(3):451-460
pubmed: 32556213
Diabetes Metab. 2020 Dec 10;47(5):101216
pubmed: 33309936
JAMA. 2010 Jan 20;303(3):235-41
pubmed: 20071471
Front Public Health. 2020 Nov 24;8:571364
pubmed: 33324596
J Infect Dis. 2021 Mar 29;223(6):945-956
pubmed: 33325510
JAMA Intern Med. 2020 Aug 1;180(8):1081-1089
pubmed: 32396163
Lancet Respir Med. 2020 Dec;8(12):1201-1208
pubmed: 32861276
Nature. 2021 Feb;590(7844):140-145
pubmed: 33137809
Nat Rev Cardiol. 2020 Dec;17(12):761-772
pubmed: 32665641
Clin Infect Dis. 2020 Dec 18;:
pubmed: 33337474
J Med Virol. 2021 Feb;93(2):695-697
pubmed: 32902868
Diabetes Care. 2015 Sep;38(9):1777-803
pubmed: 26246459
Clin Infect Dis. 2021 May 18;72(10):e558-e565
pubmed: 32856034
Diabetes Care. 2013 Sep;36(9):2690-6
pubmed: 23637354
PLoS One. 2020 Aug 26;15(8):e0238215
pubmed: 32845926
PLoS One. 2020 Dec 15;15(12):e0243600
pubmed: 33320875
Nat Rev Cardiol. 2020 Sep;17(9):543-558
pubmed: 32690910
Curr Probl Cardiol. 2020 Aug;45(8):100617
pubmed: 32402515
Lancet Diabetes Endocrinol. 2020 Oct;8(10):823-833
pubmed: 32798471